Prevention of Calbindin Recruitment into Nigral Dopamine Neurons from MPTP-Induced Degeneration in Macaca fascicularis

  • Masahiko Takada
  • Ken-ichi Inoue
  • Shigehiro Miyachi
  • Haruo Okado
  • Atsushi Nambu
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 58)

Abstract

Dopaminergic neurons in the substantia nigra pars compacta that express the calcium-binding protein calbindin selectively survive the cell death period in Parkinson’s disease. On the basis of this finding, we examined the preventive effect of calbindin recruitment into nigral dopamine neurons on toxic insults induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). A recombinant adenoviral vector encoding the calbindin gene was injected unilaterally into the striatum of macaque monkeys. One to two weeks later, expression of calbindin through retrograde transduction was observed in cell bodies of nigral dopamine neurons on the side ipsilateral to vector treatment. In these monkeys, MPTP was administered systemically by repeated intravenous injections. Parkinsonian motor signs, such as akinesia, rigidity, and flexed posture, appeared less severely in the limbs contralateral to vector treatment. Histological analysis revealed that tyrosine hydroxylase immunoreactivity in the striatum was preserved better on the calbindin-recruited side, whereas α-synuclein was expressed in nigral dopamine neurons much more strongly on the nonrecruited side. These results indicate that gene delivery of calbindin into nigral dopamine neurons protects against MPTP-induced parkinsonian symptoms in monkeys.

Keywords

Formalin H2O2 Sucrose Dopamine Tyrosine 

References

  1. Björklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS and Isacson O (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 99: 2344–2349.CrossRefPubMedGoogle Scholar
  2. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick J, Tkatch T, Meredith GE and Surmeier DJ (2007) ‘Rejuvention’ protects neurons in mouse models of Parkinson’s disease. Nature 447: 1081–1086.CrossRefPubMedGoogle Scholar
  3. Coyle JT and Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689–695.CrossRefPubMedGoogle Scholar
  4. Damier P, Hirsch EC, Agid Y and Graybiel AM (1999) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 122: 1421–1436.CrossRefPubMedGoogle Scholar
  5. Dauer W and Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39: 889–909.CrossRefPubMedGoogle Scholar
  6. During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth RH, Sladek JR Jr, O’Malley KL and Redmond DE Jr. (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 5: 820–827.CrossRefPubMedGoogle Scholar
  7. During MJ, Kaplitt MG, Stern MB and Eidelberg D (2001) Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12: 1589–1591.PubMedGoogle Scholar
  8. Fjord-Larsen L, Johansen JL, Kusk P, Tornoe J, Gronborg M, Rosenblad C and Wahlberg LU (2005) Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified neurturin construct. Exp Neurol 195: 49–60.CrossRefPubMedGoogle Scholar
  9. Gary DS, Sooy K, Chan SL, Christakos S and Mattson MP (2000) Concentration- and cell type-specific effects of calbindin D28k on vulnerability of hippocampal neurons to seizure-induced injury. Mol Brain Res 75: 89–95.CrossRefPubMedGoogle Scholar
  10. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ and Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252–255.CrossRefPubMedGoogle Scholar
  11. German DC, Manaye KF, Sonsalla PK and Brooks BA (1992) Midbrain dopaminergic cell loss in Parkinson’s disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann NY Acad Sci 648: 42–62.CrossRefPubMedGoogle Scholar
  12. Gibb WR (1992) Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson’s disease. Brain Res 581: 283–291.CrossRefPubMedGoogle Scholar
  13. Ho BK, Alexianu ME, Colom LV, Mohamed AH, Serrano F and Appel SH (1996) Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity. Proc Natl Acad Sci USA 93: 6796–6801.CrossRefPubMedGoogle Scholar
  14. Krieger C and Duchen MR (2002) Mitochondria, Ca21 and neurodegenerative disease. Eur J Pharmacol 447: 177–188.CrossRefPubMedGoogle Scholar
  15. Lavoie B and Parent A (1991) Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuroreport 2: 601–604.CrossRefPubMedGoogle Scholar
  16. Mattson MP, Rychlik B, Chu C and Christakos S (1991) Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. Neuron 6: 41–51.CrossRefPubMedGoogle Scholar
  17. McMahon A, Wong BS, Iacopino AM, Ng MC, Chi S and German DC (1998) Calbindin-D28k buffers intracellular calcium and promotes resistance to degeneration in PC12 cells. Mol Brain Res 54: 56–63.CrossRefPubMedGoogle Scholar
  18. Mouatt-Prigent A, Agid Y and Hirsch EC (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson’s disease? Brain Res 668: 62–70.CrossRefPubMedGoogle Scholar
  19. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I and Ozawa K (2002) Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13: 345–354.CrossRefPubMedGoogle Scholar
  20. Murphy AN, Bredesen DE, Cortopassi G, Wang E and Fiskum G (1996) Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 93: 9893–9898.CrossRefPubMedGoogle Scholar
  21. Orrenius S and Nicotera P (1994) The calcium ion and cell death. J Neural Transm Suppl 43: 1–11.PubMedGoogle Scholar
  22. Orrenius S, Zhivotovsky B and Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552–565.CrossRefPubMedGoogle Scholar
  23. Parent A and Lavoie B (1993) The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys. Adv Neurol 60: 25–24.PubMedGoogle Scholar
  24. Piallat B, Benazzouz A and Benabid AL (1996) Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8: 1408–1414.CrossRefPubMedGoogle Scholar
  25. Piallat B, Benazzouz A and Benabid AL (1999) Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson’s disease. J Neural Transm Suppl 55: 71–77.PubMedGoogle Scholar
  26. Schwaller B, Meyer M and Schiffmann S (2002) ‘New’ functions for ‘old’ proteins: the role of the calcium-binding proteins calbindin D-28k, calretinin and parvalbumin, in cerebellar physiology. Studies with knockout mice. Cerebellum 1: 241–258.CrossRefPubMedGoogle Scholar
  27. Smith RD, Zhang Z, Kurlan R, McDermott M and Gash DM (1993) Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52: 7–16.CrossRefPubMedGoogle Scholar
  28. Takada M, Matsumura M, Kojima J, Yamaji Y, Inase M, Tokuno H, Nambu A and Imai H (2000) Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur J Neurosci 12: 1771–1780.CrossRefPubMedGoogle Scholar
  29. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y and Hashimoto N (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115: 102–109.PubMedGoogle Scholar
  30. Verkhratsky A (2005) Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 85: 201–279.CrossRefPubMedGoogle Scholar
  31. Wilson CJ and Callaway JC (2000) Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 83: 3084–3100.PubMedGoogle Scholar
  32. Yamada T, McGeer PL, Baimbridge KG and McGeer EG (1990) Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 526: 303–307.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Masahiko Takada
    • 1
  • Ken-ichi Inoue
    • 1
  • Shigehiro Miyachi
    • 1
  • Haruo Okado
    • 1
  • Atsushi Nambu
    • 1
  1. 1.System Neuroscience Section, Primate Research InstituteKyoto University InuyamaAichiJapan

Personalised recommendations